Skip to content

Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food

Comparison of Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food and Newly Formulated Lipid Optimized Ready To Use Therapeutic Food an Individual Randomized Double Blind Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07345884
Enrollment
125
Registered
2026-01-16
Start date
2026-02-01
Completion date
2026-06-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Acute Malnutrition in Childhood, Malnutrition, Child, Neurocognition, Child

Keywords

RUTF, Ready-to-use therapeutic food

Brief summary

The goal of this randomized clinical trial is to learn if a newly formulated Lipid-Optimized Ready-to-Use Therapeutic Food (LO-RUTF) can treat severe acute malnutrition in children aged 6 to 59 months. The main questions it aims to answer are: 1. Does LO-RUTF impact physical recovery from severe acute malnutrition in participants? 2. Does LO-RUTF impact neurocognitive performance after 8 and 12 weeks of treatment? Researchers will compare LO-RUTF to standard RUTF see if our energy-dense food compares to standard issue RUTF in terms of promoting recovery from severe acute malnutrition. Participants will * Take a one-week ration of LO-RUTF or standard RUTF based on the participant's weight * Return every week for checkups, tests and to receive the next ration of assigned RUTF if eligible * Be assessed for neurocognitive function through Malawi Developmental Assessment Tool (MDAT) at three time points (before treatment, 4 weeks, 12 weeks)

Interventions

DIETARY_SUPPLEMENTLipid-Optimized Ready to Use Therapeutic Food (RUTF)

Since this is a pilot trial for the study recipe, we have increased the vitamin D3 content in this RUTF as an experimental variable within this study.

This is the standard of care RUTF with UNICEF product specifications. This RUTF will be produced internationally and shipped to Pakistan.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER
Aga Khan University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Participants in both interventions will receive approximately 190 kcal/kg/day of LO-RUTF or standard RUTF. The standard RUTF will be produced internationally and shipped to Pakistan. The alternative treatment for SAM, LO-RUTF, is produced locally in Pakistan.

Eligibility

Sex/Gender
ALL
Age
6 Months to 59 Months
Healthy volunteers
No

Inclusion criteria

* Children aged 6-59 months with severe acute malnutrition, i.e., MUAC \<11.5 cm, and/or weight-for-height/length z-score \< -3, and/or with bilateral pitting edema, with an appetite to completely consume a 30 g test feeding, and without medical complications presenting at selected rural therapeutic feeding health facilities

Exclusion criteria

* Children that are simultaneously involved in another research trial or supplemental feeding program, are developmentally delayed, have vision or hearing deficits, or have a history of milk or peanut allergy. * Chronic diseases such as malabsorption, chronic kidney disease, inflammatory bowel disease, congenital heart disease, endocrine disorders (e.g., hypothyroidism, growth hormone deficiencies), recurrent infections (e.g., pneumonia, cough, fever, pharyngitis), chronic respiratory diseases (e.g., asthma, lung diseases), congenital or acquired immunodeficiency, and neurological disorders

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Recovered from Severe Acute Malnutrition as Assessed by WHO Anthro v3.1From enrollment to the end of treatment at 8 weeksThe primary outcome is recovery from SAM, defined as: mid-upper arm circumference ≥ 11.5cm (for two consecutive weekly visits), and/or weight-for-height/length z-score \> -3 SD, and/or no bilateral pitting edema (for two consecutive weekly visits).

Secondary

MeasureTime frameDescription
Change in MDAT Scores after 8 and 12 weeks of treatmentBaseline and after 8 and 12 weeks of treatmentThe global development score along with all subdomain scores of the MDAT will be used as a measure of neurocognitive performance. with a higher score indicating a better outcome.
Time to Recovery from Severe Acute MalnutritionFrom enrollment to the end of the study period at 12 weeksDefined as time taken to recover from severe acute malnutrition, which is defined as: mid-upper-arm-circumference ≥ 11.5cm (for two consecutive weekly visits), and/or weight-for-height z-score \> -3, and/or no bilateral pitting edema (for two consecutive weekly visits).
Time to Recovery from Moderate Acute MalnutritionFrom enrollment to the end of the study period at 12 weeksDefined as time taken to achieve a mid-upper-arm-circumference ≥12.5 cm
Proportion of Participants with Relapse of Moderate Acute MalnutritionFrom enrollment to the end of the study period at 12 weeksParticipants developing moderate acute malnutrition at any point after achieving recovery from severe acute malnutrition compared to all participants
Proportion of Participants with Relapse of Severe Acute MalnutritionFrom enrollment to the end of the study period at 12 weeksParticipants developing severe acute malnutrition at any point after achieving recovery from severe acute malnutrition compared to all participants
Number of Participants with Non-Responder StatusFrom enrollment to the end of the study period at 12 weeksParticipants who have not met the SAM exit criteria after 3 months (MUAC \> 11.5 cm, clinically well, \> 15 % weight gain, and no oedema for two consecutive visits) will receive a non-responder outcome.
Incidence of Adverse EventsFrom enrollment to the end of the study period at 12 weeksNumber of participants with any adverse events, including those judged to be related to the study RUTF
Incidence of Hypercalcemia, Hypervitaminosis D, or excessive DHA concentrationsFrom baseline to the end of treatment at 8 weeksDetermined by biochemical assessments at 8 weeks to evaluate serum 25-hydroxyvitamin D, calcium, and DHA concentrations.

Countries

Pakistan

Contacts

CONTACTAhmed Moutwakil
amoutwakil@mednet.ucla.edu4244853200
PRINCIPAL_INVESTIGATORKiran K Masood, MD

University of California, Los Angeles

STUDY_DIRECTORMohid Khan

The Satya Nutrition Foundation

STUDY_CHAIRSamir Ismail

The Satya Nutrition Foundation

STUDY_CHAIRAkhila Annadanam

The Satya Nutrition Foundation

STUDY_CHAIRTu Nguyen

The Satya Nutrition Foundation

STUDY_CHAIRFatima Ahmad

The Satya Nutrition Foundation

STUDY_CHAIRMeghana Dantuluri

The Satya Nutrition Foundation

STUDY_DIRECTORAmith Umesh

The Satya Nutrition Foundation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026